drugset / Trial / NCT00828542

Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women

NCT00828542

Completed 40 enrolled University of Sao Paulo
RandomizedParallel-groupOpen-labelSupportive care

Summary

The purpose of this study to assess the safety of the etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate puerperium of healthy women.

Timeline

Start
2007-07
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Etonogestrel Unknown 68 mg Subcutaneous
Comparator medroxyprogesterone acetate Other / unclassified 150 mg Intramuscular

Indications

No indication recorded.